Potassium and magnesium orotate (Kalii orotas + Magnii orotas)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Metabolics

Included in the formulation
  • Orokamag®
    capsules inwards 
    PIK-PHARMA, LLC     Russia
  • Orokamag®
    pills inwards 
    PIK-PHARMA, LLC     Russia
    • АТХ:

    C.01.E.B   Other drugs for the treatment of heart disease

    Pharmacodynamics:

    Strengthening of reparative and regenerative processes in tissues.

    Pharmacokinetics:

    Absorption - 10%. Biotransformation in the liver to orotidin-5-phosphate. Elimination by the kidneys (30% in the form of metabolites).

    Indications:

    As an additional tool in complex therapy:

    - Ischemic heart disease (stable angina);

    supraventricular extrasystole.

    ICD-10

    IX.I20-I25.I20   Angina pectoris [angina pectoris]

    IX.I20-I25.I25.9   Chronic ischemic heart disease, unspecified

    IX.I30-I52.I49.1   Premature depolarization of the atria

    Contraindications:

    Hypersensitivity, nephrolithiasis, renal failure, cirrhosis with ascites.

    Carefully:

    Pregnancy, breast-feeding.

    Pregnancy and lactation:

    Adequate and well-controlled studies in humans and animals have not been conducted. There is no information on the penetration into breast milk. It is a part of breast milk.

    The category of FDA recommendations is not defined.

    Dosing and Administration:

    Inside in the combination therapy: 0.5-1.5 g per day in 2-3 doses (1 hour before meals or 4 hours after meals).The course of treatment is 20-40 days.

    Side effects:

    Hyperkalemia (nausea, vomiting, diarrhea, paresthesia), hypermagnia (hyperemia of the face, thirst, bradycardia, lowering blood pressure, muscle weakness, fatigue, paresis, coma, areflexia, respiratory depression, seizures), nausea, vomiting, diarrhea, pain in the epigastric region (in patients with an anatomic gastritis or cholecystitis), it is possible to develop allergic dermatoses.

    Overdose:

    Not described. Treatment is symptomatic.

    Interaction:

    Preparations of iron, tetracycline, sodium fluoride - difficulty in the assimilation of these funds (the interval between reception should be at least 2-3 hours).

    Oral contraceptives, diuretics, muscle relaxants, glucocorticoids, insulin - a decrease in the effect of orotic acid.

    Special instructions:

    Common for all salts of orotic acid:

    - intermediate product of the biosynthesis of pyrimidine bases, is normally present in the human body. In the UK it is used for liver diseases and as biologically active additives;

    - Monitoring of liver function.

    Distinctive features:

    - There is no conclusive evidence from randomized controlled trials confirming the clinical efficacy of orotic acid;

    - not available in the United States Pharmacopeia.

    Instructions
    Up